Replies to post #284382 on Innovation Pharmaceuticals Inc (IPIX)

[steelyeye]

Thanks for this... and yes, its a matter of days? weeks? No one is sitting on their laurels with the Covid-19 emergency.

Most immediately, NIAID and CDC will examine current status of safety. If there is sufficient proof, then it will almost immediately be used on patients in a real-time, in-field assessment. Patients not treated with B will serve as real-time, authentic, clinical practice controls. Efficacy will be measured against those not treated or treated with other drugs.

This is the data that, if positive, will propel IPIX to go parabolic:

...we will know if B is effective against coronavirus symptoms long before a vaccine is available. Outcomes will include measurable reduction in severity of symptoms, reduction in secondary infections, reduction of swelling and damage to alveoli, reduction in recovery time. If it meets any combination of those outcomes, testing and use will be expanded.

[TheDane]

To be a fly on the wall in the lab. Oh, my! I like your thinking...Brilicidin’s safety profile validated by CDC will put this right into human use? I can’t see why not.

We’ll see!

[warrenthomas4001]

Seems all talk is vaccine rather than antiviral. Maybe it’s just public ignorance. As a consumer, I want another vaccine like a hole in my head. The swelling numbers of Americans suffering from auto-immune disorders, which any thinking person should attribute, at least in part to this unbridled zeal for immunomodulation, and the associated accumulations, unnerves me. As a consumer, all I’m interested in is a product that attacks the virus (that may come and go like a fart in the wind) biding my immune system time to develop antibodies, and then subsequently gets eliminated from the body. In my understanding, B should not be termed a vaccine, but an antiviral, giving it an advantage both logistically and economically.

[farrell90]

Insightful post and I agree. The vaccine will not be released until its shown to be safe and effective. The Guillan-Barre outbreak after influenza vaccinations is well established.

Imo the main effect of Brilacidin will be its immunomodulating properties which hopefully will reduce the respiratory failure which is the cause of fatalities.

Brilacidin is unique in that it has the possibility of being effective in all 3 areas, an antiviral,antibiotic and immunomodulators. No other treatments have that potential.

I am hoping the government will study Brilacidin as an aerosol which would open the door for treatment of a variety of pulmonary diseases.

Glta, Farrell